Strides Pharma Science informs about company updates

10 Jul 2019 Evaluate

Further to earlier communication relating to ‘Strides to exit its investment in Arrow for AUD 394 Million’, Strides Pharma Science has informed that the transaction has achieved final closure. Strides Pharma Global, a step-down subsidiary of the Company in Singapore has received AUD 300 Million immediately at closing, while the balance AUD 94 Million will be a deferred consideration backed by a secured interest-bearing instrument. All proceeds net of transaction cost will be used to pare down debt. Strides shall retain global access to IP’s of over 140 products and has concurrently entered into a preferred supply agreement with Arrow and Apotex as the major supplier which will enable Strides to retain profits equivalent to 40%-50% of current Arrow EBITDA. 

The above information is a part of company’s filings submitted to BSE.

Strides Pharma Scien Share Price

861.10 35.75 (4.33%)
22-Jan-2026 12:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1622.40
Dr. Reddys Lab 1222.80
Cipla 1378.85
Zydus Lifesciences 885.05
Lupin 2176.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×